ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next
The European Medicines Agency’s CHMP issued a positive opinion recommending conditional marketing authorization for ImmunityBio’s Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. IBRX shares closed at $2.36 on Dec. 12, up 7.76% on heavy volume, and traded near $2.39 pre-market Dec. 15. The European Commission has not yet given final approval.